Tim Frazer

Arnold & Porter Kaye Scholer (Brussels), Arnold & Porter Kaye Scholer (London)
Lawyer (Partner)

Tim Frazer’s practice focuses on pharmaceuticals, fast-moving consumer goods, financial services and IP-rich sectors. He advises on both conduct and merger cases in the EU and UK, and on compliance and audit processes in various jurisdictions worldwide that have adopted the EU approach to competition law. He also represents clients challenging public procurement tenders under EU and UK rules. He has obtained merger clearance at the European Commission and national competition authorities for complex cases requiring econometric evidence and Phase 1 or Phase 2 disposals, such as: the joint venture between the Douwe Egberts and the coffee businesses of Mondelēz International; Kraft Foods’ hostile bid for Cadbury plc and Kraft Foods/Danone. He is currently representing Monsanto in relation to the clearance outside North America of the proposed acquisition of the company by Bayer. He represented a pharmaceutical client involved in one of the Competition and Markets Authority’s first dawn raids, defending it in an abuse of dominance investigation. He advises pharmaceutical and medical device companies on pricing, parallel trade and supply chain design. He divides his time between the firm’s London and Brussels offices. He is the author of several books on competition law and was previously a Professor and Dean of Law at Newcastle University.

Linked authors

RBB Economics (Brussels)
DG COMP (Brussels)
Latham & Watkins (San Francisco)
Arnold & Porter Kaye Scholer (Washington)
American Urological Association and Urology Care Foundation

Articles

157 Bulletin

Diane E. Bieri, Jonathan Gleklen, Kelly Smith Fayne, Tim Frazer The U.S. Supreme Court holds that “reverse payment” patent settlements between brand-name drug manufacturers and would-be generic competitors should be reviewed under the antitrust rule of reason (Actavis)

157

On Monday, June 17, the Supreme Court handed down a decision in FTC v. Actavis, Inc., bringing some clarity to the antitrust treatment of so-called reverse payment patent settlements between brand-name drug manufacturers and would-be generic competitors, but leaving many open questions as (...)

Send a message